P123 Safety and efficacy of filgotinib, an update from the DARWIN 3 phase 2 long-term extension with a maximum of 8.2 years of exposure von Emery, Paul, Westhovens, Rene, Alten, Reike H E, Dagna, Lorenzo, Kavanaugh, Arthur, Winthrop, Kevin L, Barry, Jane, Besuyen, Robin, Corallo, Claudio, Watson, Chris, Martin, Nicolas, Genovese, Mark, Spindler, Alberto J, Stanislavchuk, Mykola, Greenwald, Maria

Volltext